Background: The use of combination antiretroviral therapy (cART) has substantially improved the outlook for patients with HIV infection. However, lifelong exposure to cART is also associated with adverse metabolic changes and an enhanced risk of renal, hepatic, and cardiovascular dysfunction. This study investigated disruptions of the urinary metabolome of cART-exposed patients, thereby furthering our understanding of some of the side effects of pharmaceutical intervention.
INTRODUCTION
The introduction of combination antiretroviral therapy (cART) has transformed HIV infection from a life-threatening disease into a chronic condition. Multiple comorbidities not associated with AIDS, such as cardiovascular, renal, bone, and hepatic diseases, are becoming more prevalent in HIVpositive individuals compared with those without the infection. 1 Although the aging process and the virus itself might play an important role in the development of non-AIDS comorbidities, the cumulative effects of cART have been associated with the onset and progression of non-AIDS comorbidities in HIV infection. For instance, nucleotide reverse transcriptase inhibitors (NRTIs), such as tenofovir disoproxil fumarate (TDF), have been linked with proximal tubular renal disease and reduced bone mineral density, 2, 3 whereas abacavir has been found to increase the risk of ischemic heart disease in cohort studies. 4 Protease inhibitors (PIs), another class of antiretrovirals frequently used in clinical practice, have been widely associated with complications, such as dyslipidemia, abnormal fat distribution, and insulin resistance. [5] [6] [7] Currently, it is not possible to predict which patients are more likely to develop a particular non-AIDS comorbidity after starting cART. Therefore, there is an urgent need for biomarkers that can predict and guide therapy in people living with HIV affected by non-AIDS comorbidities. The use of a discovery-based untargeted metabolomics approach may help to further elucidate mechanisms of action, metabolism, and toxicity associated with the use of cART. 8 This analytical approach allows the profiling of a wide range of metabolites in a patient's biofluids, such as urine and blood, and therefore has great potential for the discovery of biomarkers of pharmaceutical efficacy and toxicity in HIV infection. To date, the effect of cART exposure on urinary metabolite profiles has not been studied using trace analytical methods, yet analysis of this biofluid may provide a useful noninvasive screen for pharmaceutical efficacy and toxic side effects arising from exposure to combinations of NRTIs and PIs.
This study aims to investigate the effect of 2 cART regimens on the urinary metabolome in comparison with cART-naive HIV-positive and negative patients. Urine samples were extracted and analyzed using, for the first time, highly sensitive nanoflow liquid chromatography-nanoelectrospray-mass spectrometry methods, which enable sensitive nontargeted analysis of urine samples to detect disruption in metabolite profiles associated with cART intervention.
METHODS

Study Population
Fasted urine and plasma samples were collected between 2010 and 2011 from HIV-positive patients participating in a longitudinal study investigating reduced bonemineral density in HIV-positive men from a single HIV outpatient clinic in Brighton, UK.
9 HIV-negative men were recruited from a single sexual health clinic in Brighton. All subjects were white males, and exclusion criteria were men (HIV-infected and HIV-negative) ,18 years old, patients unable to give written informed consent, patients who have had imaging with contrast in the previous 48 hours, or are infected with hepatitis C virus, showing moderate to severe hepatotoxicity, renal insufficiency, or reduced bone mineral density at the time of sampling. Participants were classified into 3 study groups: HIV-positive on cART, HIV-positive cART-naive, and HIV-negative. For all study groups, demographic and HIV parameters, including age, ethnicity, current and nadir CD4 cell count, current HIV viral load, time since HIV diagnosis, and time since initiating cART were obtained from the main study clinic database. Ethical approval was given by the NHS Research Ethics Committee (NREC 09/H1107/101), and all patients gave written informed consent.
cART Regimens and Urine Sample Collection HIV-positive patients on cART were on a combination of TDF, emtricitabine, and the PI booster ritonavir. Additionally, they were also on either PI atazanavir or darunavir, which was the only way in which the cART regimens differed. The characteristics and structures of the pharmaceuticals used in cART are given in Supplemental Digital Content, Table S1 , http://links.lww.com/QAI/A894 and Supplemental Digital Content, Figure S1 , http://links.lww.com/QAI/A891.
Urine osmolality was measured using a Model 3320 osmometer (Advanced Instruments Inc., Norwood, MA) and an aliquot of the remaining sample was frozen at 280°C in 10% methanol before sample extraction for metabolomics analyses.
Targeted Plasma and Urine Biochemistry
All blood plasma and urine chemistries were performed on a Cobas Integra 800 analyzer (Roche Diagnostics, Burgess Hill, United Kingdom). Total protein concentration in urine was measured by turbidimetry after alkaline denaturation and precipitation with benzethonium chloride, with a measuring range of 40-2000 mg/L. Imprecision (analytical error) was 3.9% at 55 mg/L and 2.5% at 260 mg/L. Urine albumin was measured by immunoturbidimetric assay using polyclonal sheep anti-human albumin antisera with a working analytical range of 12-200 mg/L. Imprecision was 2.0% at 20 mg/L and 2.3% at 120 mg/L. Samples with a concentration above these upper limits were automatically rerun at dilution. Urine creatinine concentration was determined by enzymatic (creatininase) colorimetry with a measuring range of 0.1-40.0 mmol/L and imprecision was 1.8% at 5.8 mmol/L and 3.6% at 25.6 mmol/L.
Metabolomics Analyses of Urine Samples
Full details of urine extraction methods and their analyses are given in the supplementary information. Briefly, urine was extracted as previously described by our laboratory, 10 and extracts were reconstituted to give a final osmolality of 1360 mOsm before MS analysis. 11 Quality control (QC samples) and sample extracts were analyzed by nanoflow ultrahigh-performance liquid chromatographynanoelectrospray ionization-time-of-flight mass spectrometer (nUHPLC-nESI-TOFMS) as described in recent studies. 12 This analytical methodology allows profiling of a wide range of small-molecule metabolites present in urine samples, including steroids, lipids, neurotransmitters, peptides, and nucleotides. 10 MS data sets were processed and analyzed by multivariate modeling, including principal components analyses (PCA) and orthogonal partial least squares-discriminant analysis (OPLS-DA), to identify metabolite differences between treatment groups. Discriminating metabolites of cART intervention were detected using S-plots from OPLS-DA models, which were constructed for atazanavir versus cART-naive patients and for darunavir versus cARTnaive patients. After the exclusion of ions associated with the parent cART drugs and their metabolites, further OPLS-DA models and S-plots were constructed between the cARTnaive and cART groups to identify endogenously derived metabolites that were markers of cART treatment. Metabolite identities were determined from their accurate mass, isotopic fit, and comparison of fragmentation data with authentic standards or metabolite databases.
Statistical Analyses
Univariate statistical analysis of urinary marker metabolites (and targeted blood biochemistry) was performed using SPSS version 22 (IBM, New York, NY). Metabolites were tested for normality and for significance at P , 0.05 using a 1-way analysis of variance with a Games-Howell test (because of unequal variances) to determine P values. Nonnormally distributed data were log 10 transformed before analysis of variance. A false discovery rate of 5% was used to check for the occurrence of type 1 errors arising from multiple testing. 13 Linear regression modeling was used to adjust for the confounding effects of age and urine protein/creatinine ratio (uPCR) (see results in Table 1 ) on the association of metabolite disruptions in the different patient groups.
RESULTS
Patient Data and Targeted Blood Biochemistry
In total, samples from 89 patients were analyzed, comprising 13 cART-naive HIV-negative patients, 26 cART-naive HIV-positive patients, and 50 HIV-positive patients on cART. Of these 50 patients, 20 were on atazanavir and 30 were on darunavir. All patients, except one, were on the specified cART regimen for at least a month before sampling: those on atazanavir for a mean (SD) period of 16.8 (11.0) months and darunavir for 12.9 (7.0) months.
Clinical data for patient groups are summarized in Table 1 . All subjects were white males aged between 20 and 71 years. All HIV-positive patients on cART had a plasma HIV viral load ,40 RNA copies per milliliter in contrast to the high and variable viral load in the cART-naive HIV-positive group (Table 1) . Nadir CD4 counts were lower in those on cART, but at the time of urine sampling, there was no difference in CD4 cell counts measured between those on cART and those that were cART-naive. There were also no clear indications of major kidney or liver toxicity for those on atazanavir or darunavir. However, the uPCR, a marker of kidney injury, was significantly increased in those on cART compared with the HIV-negative patients, but values in all study groups were within the reference range. The urine albumin creatinine ratio, another marker of kidney disease, remained unchanged in those on cART. Bilirubin and alkaline phosphatase levels were, as expected, increased in the atazanavir group compared with the cARTnaive and darunavir groups; this is a common side effect of atazanavir medication due to disrupted biliary excretion.
14 Plasma triglyceride and cholesterol levels were significantly increased in the darunavir group compared with the cART-naive and HIV-negative groups, respectively. There was no significant variation in free or total testosterone levels in plasma; however, steroid hormone binding globulin levels were significantly higher in patients on cART compared with the HIV-negative group.
Metabolomic Analysis of the Effect of cART Treatment
Analyses of the QC samples revealed highly repeatable data indicating acceptable extraction and MS instrumental performance (see Supplementary Results). The Study groups were 100% white males. Values are mean (SD) with the exception of CD4 count and viral load, which are reported as median (range). Values in bold are significantly increased compared with HIVnegative or the cART-naive group. P values for comparison with HIV-negative/cART-naive groups are given in superscript. Limit of detection of viral load was 40 RNA copies per milliliter plasma.
ALP, alkaline phosphatase; ALT, alanine transaminase; NA, not applicable; ND, not determined; SHBG, steroid hormone binding globulin; uACR, urinary albumin creatinine ratio; uAPR, urinary albumin protein ratio; uPCR, urinary protein creatinine ratio. urinary metabolomic profiles of individuals taking the 2 cART regimens were compared with cART-naive HIV-positive and HIV-negative groups using PCA modeling. The data sets comprised 6705 and 9043 MS features in the positive and negative mode, respectively. Grouping of patient samples on plots of both scores of data obtained in + and 2 nESI modes were similar and revealed no discrimination between the metabolomic profiles of urine from cART-naive and HIVnegative patients (Figure 1 and Supplemental Digital Content, Figure S2 , http://links.lww.com/QAI/A892). Patients on cART regimens containing either atazanavir or darunavir clustered separately and away from the cART-naive group. In +nESI, the 2 cART treatment groups were separated from the cART-naive group on the first component and from each other on the second component, whereas in 2nESI, discrimination was only observed on the first component.
Identification of cART Drugs and Metabolites
Discriminating metabolites of cART intervention were detected using S-plots from OPLS-DA models (Figure 2 and Supplemental Digital Content, Figure S3 , http://links.lww. com/QAI/A893 for examples). The majority of the discrimination between the cART-naive and exposed groups was driven by ions associated with the cART drugs and their metabolites. A total of 16 structures were identified, 4 of which were the parent drug compounds, and the remaining were metabolites of 3 PIs (Table 2 and Supplemental Digital Content,  Table S2 , http://links.lww.com/QAI/A895). Identification of the metabolites was supported by fragmentation patterns that were compared with those of metabolite structures that had already been detected in rodent urine, human blood, and hepatocyte studies. [15] [16] [17] [18] Analysis of the OPLS-DA loadings plot for each cART parent compound confirmed that all but one urine sample contained cART drugs at the time of sample donation. As none of the parent drugs, nor any of their metabolites, were detected in urine extracts from this patient in the darunavir group, this sample was excluded from further statistical analyses.
Effect of cART Intervention on the Endogenously Derived Metabolome
After the exclusion of ions associated with the parent cART drugs and their metabolites, further OPLS-DA models were constructed to identify endogenously derived metabolites that were associated with cART treatment. Interrogation of the S-plots uncovered 13 endogenous metabolites that discriminated between the sample groups after accounting for a false discovery rate of 5%. These included 5 bile acids/ alcohols, 4 conjugated androgens, and a nucleoside, lipid, FIGURE 1. PCA scores plot analysis of the effect on the urinary metabolome of HIV and cART status (+nESI mode). cART-exposed groups received the NRTIs tenofovir disoproxil fumarate and emtricitabine, and the ritonavir PI as well as either atazanavir or darunavir (labeled respectively). QC represent quality control samples (n = 8). No discrimination was detected between the HIVnegative and HIV-positive cART naive patients. However, both groups on cART discriminated from the cART-naive and HIVnegative patients on the first component and cART groups clustered separately from each other on the second component.
peptide, and unidentified metabolite. Details of the determination of metabolite identity after fragmentation of the molecular ion are given in Supplemental Digital Content, Table S3 , http://links.lww.com/QAI/A896. The effect of age and uPCR as potential confounding variables influencing the association of the urinary metabolites with cART status was analyzed using linear regression modeling. After adjusting for confounders, the analysis revealed that 12 metabolites were significantly decreased in urine of cART-exposed groups patients compared with either the cART-naive and/ or HIV-negative groups. One metabolite, a tetrapeptide, was found to be significantly increased in urine in the atazanavir cART group than in the cART-naive group (Table 3) .
DISCUSSION
Metabolism of cART Drugs
An advantage of using a global metabolomics analysis of urine samples is that both exogenously derived compounds, such as administered drugs and other xenobiotics, are detected as well as changes in endogenously derived biochemical metabolites. In this study, the parent compounds of all 3 PIs and 2 NRTI drugs were detected in urine samples from cARTexposed groups. The PIs were also highly metabolized by each patient, whereas only the parent NRTIs, tenofovir, or emtricitabine were detected in urine extracts in keeping with previous studies indicating that these compounds are poorly metabolized in the humans. 19, 20 In agreement with previous in vitro studies, 2 metabolites of ritonavir were detected in urine extracts (the oxidized and deacylated products); however, the glutathione conjugate was not detected, and this metabolite may have preferentially been excreted by the biliary route. 15 The detection of a number of metabolites of atazanavir and darunavir in this study agreed with previous work showing that these pharmaceuticals are extensively metabolized in humans through oxidation, carbamate hydrolysis, deacylation (atazanavir), and glucuronidation (darunavir). 16, 17 The ability to detect the parent cART drugs and a wide range of their transformation products in urine extracts suggest that in future studies, links between pharmacogenetics, metabolism, and drug efficacy could be investigated, which may lead to a more personalized approach to cART intervention. In addition, it is also possible to identify FIGURE 2. OPLS-DA S-plot analysis of metabolite profiles in urine samples of patients on cART containing darunavir compared with cART-naive patients. Samples were analyzed in +nESI mode. Each dot represents a spectral signal corresponding to retention time/m/z ion of a metabolite. Signals in the bottom left corner of the plot decreased in the cART-exposed group when compared with the cART-naive group. Signals in the top right corner increased in the cART group and were associated with ions corresponding to cART pharmaceuticals and their metabolites (Table 2 and Supplemental Digital Content, Table S2 , http://links.lww. com/QAI/A895 for cART metabolite identities).
individuals who have not taken the medication, which was evident for one patient in our study from the darunavir group in whom neither darunavir nor any of its metabolites or any other cART drugs were detected in their urine sample.
Variation in the Endogenous Metabolome as a Result of cART
The PCA scores plot (Figure 1 and Supplemental Digital Content, Figure S2 , http://links.lww.com/QAI/A892), as well as further modeling studies using OPLS-DA, did not reveal any discrimination between the cART-naive and HIV-negative groups despite their different HIV statuses. Furthermore, stratification of the cART-naive group by nadir or current CD4 count into 2 groups (#250 and $250 cells/mL) did not result in discrimination between these sample groups. A possible explanation is that metabolomic changes associated with immunosuppression may not be detected in urine samples from HIV-positive patients. Instead, analyses of blood samples may elucidate early-stage metabolomic consequences of HIV infection. Other studies analyzing blood samples from cARTnaive patients with HIV report disrupted lipid and carbohydrate metabolism and changes in organic acids associated with oxidative stress and disturbed mitochondrial metabolism. 8, 21 In this study, 12 metabolites were detected, which decreased in the urine of HIV-positive patients on cART. Of these, 4 were bile acids, which, depending on the metabolite and after adjusting for confounding variables, were detected at between 2 and 80 times lower levels in the urine from both cART groups (Table 3 ). In contrast, previous studies have detected increased levels of plasma bile acids in patients receiving cART or PIs. 22, 23 Plasma concentrations of bile acids were not measured in our study, but blood ALT levels did not suggest significant liver damage. However, plasma/hepatocyte concentrations of bile acids are also influenced by cell membrane transporters such as organic anion-transporting polypeptides (OATPs) and 2 subtypes, OATP2B1 and OATP1B1, are inhibited by PIs including atazanavir, darunavir, and ritonavir. [24] [25] [26] In addition, apical membrane transporters such as ATP-binding cassette transporter B11 (ABCB11), which export bile acids from the hepatocytes into the bile, are also inhibited by PIs. [27] [28] [29] These transporters are also present in the apical membrane of proximal tubules of the kidney. 30, 31 Thus, they may be involved in the excretion of bile acids into the urine, and if inhibited by PIs, this may result in decreased levels of urinary bile acids. However, in this study, only a subset of the total bile acids that were present in the urine extracts were disrupted (Supplemental Digital Content, Table S4 , http://links.lww.com/QAI/A897), which implies that these transporters may have different affinities for the various bile acids.
The results show lower concentrations of a bile alcohol, cholestanehexol glucuronide, in the urine of patients on cART. Bile alcohols are end products of cholesterol metabolism and are minor components in the bile and urine of healthy subjects. However, increased concentrations of conjugated bile alcohols have been detected in patients with primary biliary cirrhosis, an autoimmune disease. 32 Similar to bile acids, they may be markers of liver function or indicate disruption of bile metabolism and transport as a result of cART intervention.
Concentrations of a number of conjugated androgens, major urinary metabolites of testosterone, were reduced in the cART-exposed groups. Reduced plasma concentrations of pregnenolone, androsterone, and dehydroepiandrosterone sulfates have been reported in patients on cART. 22 It has been suggested that type 1 interferons, which are markers of innate immune activation, may downregulate sterol metabolism during antiviral responses. 33 However, it was observed that plasma levels of free and total testosterone were not significantly different between sample groups (Table 1) , which suggests that other mechanisms, such as inhibition of androgen transport in the kidney epithelium, may be responsible for decreased levels of androgens in the urine of cART-exposed groups. In addition, levels of steroid hormone binding globulin, an important carrier protein for sex steroids, were elevated in both groups on cART, which may have resulted in increased binding of free androgens in plasma and less availability for metabolism and conjugation. Another important finding in our study was the identification of the nucleoside 5-deoxy-5(methylthio) adenosine, which was decreased in the urine of cARTtreated HIV-positive patients. This metabolite has previously been detected at elevated levels in the urine of immunocompromized children. 34, 35 It is believed to regulate cell apoptosis through the inhibition of protein carboxymethyltransferase, which can modulate cell signaling and protein expression through protein methylation. 36, 37 This potential role in apoptosis may be relevant in HIV disease, which is a major cause of CD4 cell loss. 38, 39 Furthermore, 5-deoxy-5(methylthio)adenosine is involved in the activation of lymphocytes and thus may also be elevated as part of the immune response to HIV infection. 36 The possible role of 5-deoxy-5(methylthio) adenosine in HIV disease requires further investigation.
Concentrations of a C17 hydroxysphinganine type of lipid were reduced in both HIV-positive groups on cART. To our knowledge, this is the first time this metabolite structure has been detected in human biofluids. However, a C17 sphinganine has been detected in human plasma as a biomarker of kidney cancer. 40 The role of sphingolipid bases in HIV infection is currently unknown, but sphingolipids and their metabolites can initiate cellular apoptosis, 41 regulate HIV viral entry into cells, 42, 43 and are associated with agerelated changes in cholesterol/low-density lipoprotein levels. 44 Concentrations of a tetrapeptide increased in patients on atazanavir, possibly as a result of TDF and reduced proximal tubular function and reduced reuptake of low-molecularweight proteins. 45, 46 The effects of PI intervention on urinary protein and peptide profiles require further investigation.
To conclude, this first study using trace metabolomic analyses of urine from an HIV cohort has revealed a number of metabolite disruptions in the urine of cART-exposed patients, which need to be further investigated to determine their association with the side effects of pharmaceutical intervention. However, this study has some limitations. As all the patients were male and white, these results cannot be extrapolated to other groups of HIV-positive patients, including HIV-positive women and those of nonwhite ethnicity. Additionally, because of the cross-sectional nature of the study, direct causality with pharmaceutical intervention cannot be inferred. Future studies using larger sample sizes and comparing blood and plasma metabolomic profiles in longitudinal cohorts before, and during, pharmaceutical intervention will aid understanding of cART-related toxicity in patients.
